Xilio Therapeutics, a biotech company, received $35.8 million in gross proceeds from Series B warrant exercises, extending anticipated cash runway. They achieved a development milestone for a masked antibody-based program and nominated a development candidate for a T cell engager program targeting CLDN18.2. Sara Bonstein was appointed as the chair of the board of directors. Xilio highlighted upcoming milestones, including submitting an investigational new drug application and reporting Phase 1 data. Financially, they estimate having $137.5 million in cash and cash equivalents, enough to fund operations into the second quarter of 2027.

Read more at Barchart: Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates